A Dose of Reality with Charles Spence27 Apr 2025

Joseph Birkett, Executive Director at Aura Biosciences – Obinutuzumab's Approval, CDK9 Trial Regret, CRO Reliance, and Building Respectful Cultures

Joseph (Joe) Birkett, Executive Director of Medical Affairs at Aura Biosciences, joined our podcast to share what he’s learned over two decades in oncology drug development, including the career-defining moments and the painful missteps that shaped his approach.

Joe speaks openly about his proudest contribution—helping lead Obinutuzumab to regulatory approval—and contrasts it with one of his lowest points: watching leadership ignore safety concerns around a CDK9 inhibitor that ultimately failed in the clinic.

Here's what you're in:

How Joe helped lead Obinutuzumab to Phase III and approval.
The fallout of pushing a CDK9 inhibitor with flawed preclinical data.
His experience as a CEO and the lessons he carries forward.

Timestamps:

02:22 Working on Obinutuzumab and its approval

04:51 Dealing with toxic leadership and moving on

07:18 Introducing Aura Biosciences

15:01 What Joe looks for when hiring at Aura

19:32 Why companies rely too much on CROs

24:44 The problem with safe bets and risk-averse R&D

29:47 Quickfire round

About Joe

Joseph Birkett is the Executive Director of Medical Affairs at Aura Biosciences, a clinical-stage biotech company developing virus-like drug conjugates (VDCs) to treat cancers such as uveal melanoma. Joe has 25 years of oncology drug development experience, contributing to the approval of seven oncology drugs across multiple disease areas.

Prior to joining Aura Biosciences, he served as CEO of a stealth-mode EU biotech and is the founder of Crest Pharma. He holds a PhD in Psychiatric Medicine from King’s College London, and his passion extends beyond drug development to longevity, health, and wellness.

Connect with Joe

LinkedIn: https://www.linkedin.com/in/joseph-birkett-14572410/

Company Website: https://www.aurabiosciences.com/

About me

My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.

Connect with me:

LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/

Website: https://www.discera-search.com/

Opinions and comments expressed by the guest do not represent the company and are fully their own.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(74)

Eliot Forster, CEO at Levicept on 30 Years in Pharma, Running a Six-Person Biotech, and the Future of European Drug Development

In this episode, I talked with Eliot Forster, CEO of Levicept, a neurophysiologist-turned biotech veteran with 30+ years of experience across Big Pharma and a series of CEO roles. We get into clinical...

7 Sep 45min

Michael Zaiac, Medical Affairs Lead for Oncology at Daiichi Sankyo on 30 Years of Hiring Lessons, The ADC Wave, and Building Teams in a Fast-Moving Pipeline

In this episode, I talked with Michael Zaiac, Medical Affairs Lead for Oncology across Europe and Canada at Daiichi Sankyo — a trained surgical oncologist who walked away from the operating table, mov...

24 Aug 39min

Juho Jalkanen, CEO at Faron Pharmaceuticals on From Surgeon to CEO, Rethinking Boards, and Fighting for the Right Science

In this episode, I talked with Dr. Juho Jalkanen, CEO of Faron Pharmaceuticals — a publicly listed Finnish biotech building novel immunotherapies for blood cancers. Juho's path is unlike most you'll h...

10 Aug 37min

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

In this episode, I talked with Dr. Tobias Kampfenkel, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine. Tobias spent nearly a decade at Janssen building ...

15 Juni 39min

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

In this episode, I talked with Sofia Heigis, Chief Executive Officer of OncoPeptides, about a career path that did not start where she expected. Sofia originally wanted to move into clinical operation...

31 Maj 38min

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

In this episode, I talked with Jens Lindberg, CEO of Medivir AB, a Swedish biotech developing innovative therapies in liver cancer and rare disease. Jens brings over 30 years of late-stage development...

18 Maj 33min

Hubert Truebel, Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

In this episode, I talked with Hubert Truebel, Managing Director at DEBRA Research, to discover a career that wasn’t built traditionally—but through creating opportunities where none formally existed....

4 Maj 28min

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

In this episode, I talked with Sampreet Ramachandra, Head of the Hematology Business Unit at Novartis Germany, about what it really takes to lead high-stakes launches — and what leadership looks like ...

30 Mars 42min